A5052333362- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Peripheral Neuropathies and Disorders
- SARS-CoV-2 and COVID-19 Research
- Multiple Myeloma Research and Treatments
- Telomeres, Telomerase, and Senescence
- Bacterial Infections and Vaccines
- Parkinson's Disease Mechanisms and Treatments
- Medication Adherence and Compliance
- Misinformation and Its Impacts
- Acute Lymphoblastic Leukemia research
- Virology and Viral Diseases
- Full-Duplex Wireless Communications
- Rheumatoid Arthritis Research and Therapies
- Family and Disability Support Research
- Immune Response and Inflammation
- Lymphadenopathy Diagnosis and Analysis
- Neuroinflammation and Neurodegeneration Mechanisms
- T-cell and B-cell Immunology
- Autoimmune and Inflammatory Disorders Research
- Genetic Associations and Epidemiology
- Circular RNAs in diseases
- Monoclonal and Polyclonal Antibodies Research
- Reproductive System and Pregnancy
- Viral Infections and Immunology Research
Monash University
2020-2025
Alfred Health
2020-2025
The Alfred Hospital
2021-2024
Monash Health
2019
The University of Melbourne
2013-2015
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disease of the central nervous system. There were 33 335 people with MS in Australia 2021 2917 New Zealand 2006 prevalence incidence are increasing time. Although new treatments have substantially improved outcomes recent decades, treatment landscape has become increasingly complex due to expanding number disease-modifying therapies (DMTs) associated safety considerations. A total 80 consensus recommendations...
Background Ongoing controversy exists regarding optimal management of disease modifying therapy (DMT) in older people with multiple sclerosis (pwMS). There is concern that the lower relapse rate, combined a higher risk DMT-related infections and side effects, may alter risk-benefit balance pwMS. Given lack pwMS above age 60 randomised controlled trials, comparative efficacy high-efficacy DMTs such as ocrelizumab has not been shown We aimed to evaluate effectiveness ocrelizumab, DMT, versus...
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system with rapidly evolving treatment options strategies. An iterative modified Delphi process was used to develop 80 consensus recommendations for management MS in Australia New Zealand. Part 1 these guidelines includes related selection initial disease-modifying therapy (DMT) MS, assessments before commencing DMT, monitoring activity on switching discontinuing DMT. This article, 2,...
In spite of the recognized physical and psychosocial effects caring for patients with Parkinson's disease (PD), caregiver burden (CB) in this setting is poorly understood. The objective research was to identify factors that were associated CB an Australian population PD caregivers using a novel instrument - Disease Caregiver Burden (PDCB) questionnaire.Fifty patient-caregiver couples recruited from three movement disorders clinics Melbourne, Australia. on rated PDCB questionnaire. scores...
Existing instruments for caregiver burden assessment are not specific or sensitive to various aspects of caring patients with Parkinson's disease. A better understanding may enhance patient care and improve health both caregiver. The goal this study was evaluate the validity Disease Caregiver Burden (PDCB) questionnaire, a novel instrument designed appraise more accurately experienced by caregivers in setting disease.Common sources distress were taken from discussions disease patients,...
Ocrelizumab is an anti-CD20 monoclonal antibody (mAb) that has been shown in phase 3 clinical trials to reduce relapses and disease progression multiple sclerosis (MS) patients. Prior the approval of ocrelizumab, rituximab, a chimeric mAb was used treat MS. Rituximab still MS many countries outside Australia remains mainstay treatment non-MS neuroimmunological systemic inflammatory diseases. currently neuromyelitis optica spectrum disorder (NMOSD) autoimmune encephalitis, addition its...
Background: Increasingly, people with relapsing-remitting multiple sclerosis (RRMS) are switched to highly effective disease-modifying therapies (DMTs) such as ocrelizumab. Objective: To determine predictors of relapse and disability progression when switching from another DMT Methods: Patients RRMS who ocrelizumab were identified the MSBase Registry grouped by prior therapy (pDMT; interferon-β/glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod or natalizumab) washout duration...
Background: The COVID-19 pandemic challenges multiple sclerosis services to be innovative in delivering infusible therapies. To reduce time clinical settings, and potential staff or space losses, we implemented rapid infusion protocols for selected patients.Objective: analyse the rate of related reactions patient experience infusions natalizumab ocrelizumab. document reduction patients spent settings during pandemic.Methods: Patients with prior exposure at least three two 300mg ocrelizumab...
Background In Australia, tixagevimab/cilgavimab 150 mg/150 mg was a government-funded pre-exposure prophylaxis for COVID-19 people with multiple sclerosis (pwMS) and other neuroimmunological conditions (pwNIc) treated anti-CD20 antibodies or sphingosine-1-phosphate receptor modulators were eligible. Objective To analyse the roll-out, uptake real-world efficacy of in prevention severity COVID-19. assess compliance depending on location delivery. Methods We undertook single-centre study. 440...
People with multiple sclerosis and neuroimmunologic disorders (herein referred to as patients) are increasingly treated infusible monoclonal antibodies. This rise in demand has placed increased loads on current infusion services mandates careful strategic planning. study examined patient preferences for the timing location of infusions their association demographic disease variables facilitate patient-focused planning.Ninety-one patients receiving an therapy at service during March 2019 were...
Aging-related processes contribute to neurodegeneration and disability in multiple sclerosis (MS). Biomarkers of biological aging such as leukocyte telomere length (LTL) could help personalise prognosis. Pregnancy has been shown be protective against accumulation women with MS, though it is unclear if this effect relates mechanisms or LTL.
Patients with relapsing-remitting multiple sclerosis commonly switch between disease-modifying therapies (DMTs). Identifying predictors of relapse when switching could improve outcomes.To determine hazard to cladribine.Data patients who switched cladribine, grouped by prior therapy (pDMT; interferon-β/glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod or natalizumab (NTZ)), were extracted from the MSBase Registry. Predictors during treatment gap and first year cladribine...
<h3>Background</h3> In Australia, Evusheld – (tixagevimab150mg and cilgavimab150mg) is currently the only pre-exposure prophylaxis for COVID-19 infection Persons with Multiple Sclerosis (pwMS) who are treated anti-CD20 antibodies sphingosine 1- phosphate receptor modulators have an impaired vaccine-induced immune response, resulting in increased risk of severe infection. The uptake efficacy real-world MS populations not known forms basis this study. <h3>Objective</h3> To analyse uptake,...
<h3>Background</h3> Ageing-related processes contribute to neurodegeneration and disability in multiple sclerosis (MS). Biomarkers of senescence such as leukocyte telomere length (LTL) could help personalise prognosis treatment. A history pregnancy has been shown be protective against accumulation women with MS<sup>1</sup>: it is unclear if this partly mediated by LTL. We aimed cross-sectionally characterise LTL an MS cohort, correlate history. <h3>Methods</h3> extracted DNA from the whole...